Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Research Protocols

Date Submitted: Apr 2, 2026
Date Accepted: Aug 11, 2026

The final, peer-reviewed published version of this preprint can be found here:

Evaluation of a Mental Health Care App–Based Fatigue Management Program for Patients With Inflammatory Bowel Disease in Remission: Protocol for a Randomized Controlled Trial

Tanaka M, Wakai S, Sakagami K, Kawakami A, N.Takashina H, Kang J, Nagahori M, Ito H

Evaluation of a Mental Health Care App–Based Fatigue Management Program for Patients With Inflammatory Bowel Disease in Remission: Protocol for a Randomized Controlled Trial

JMIR Res Protoc 2026;15:e96593

DOI: 10.2196/96593

PMID: 42803779

Evaluation of a mental health care app-based fatigue management program for patients with inflammatory bowel disease in remission: A randomized controlled trial protocol

  • Makoto Tanaka; 
  • Sayaka Wakai; 
  • Kayoko Sakagami; 
  • Aki Kawakami; 
  • Hikari N.Takashina; 
  • Jeongae Kang; 
  • Masakazu Nagahori; 
  • Hiroaki Ito

ABSTRACT

Background:

Fatigue remains a major unresolved issue affecting the quality of life of patients with inflammatory bowel disease (IBD), even during clinical remission. Scalable psychological approaches are needed to support effective fatigue management.

Objective:

The aim of this study is to evaluate the effectiveness of a mental health care app for fatigue management among patients with IBD in remission and to explore factors related to its acceptability and effectiveness.

Methods:

This is an open-label, waitlist randomized controlled trial. Eligible participants are adults (≥18 years) diagnosed with Crohn’s disease or ulcerative colitis who meet remission criteria and have at least mild fatigue. Participants will be randomized 1:1 using stratified block randomization based on disease type, sex, and baseline fatigue severity. The intervention consists of a seven-week cognitive-behavioral therapy-based educational program with supportive messages. The primary outcome is fatigue, measured using the Functional Assessment of Chronic Illness Therapy–Fatigue (FACIT-F), and the secondary outcome is self‑efficacy, measured using the Inflammatory Bowel Disease Self‑Efficacy Scale Short Form (IBD-SES13). A sample size of 175 participants per group is required.

Results:

Recruitment of participants began on July 28, 2025, and closed on February 24, 2026. A total of 502 patients with IBD in clinical remission were invited to participate in the study. Among them, 351 met the eligibility criteria and were randomized, while 151 (30%) had FACIT-F scores of 41 or higher and were excluded. Follow-up is ongoing.

Conclusions:

This study may contribute valuable knowledge regarding the feasibility, acceptability, and potential impact of app‑based psychoeducation on fatigue in patients with IBD. The findings will support future refinement of the intervention and inform large-scale evaluations and implementation efforts. Clinical Trial: The University Hospital Medical Information Network UMIN000057278 https://center6.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000065453


 Citation

Please cite as:

Tanaka M, Wakai S, Sakagami K, Kawakami A, N.Takashina H, Kang J, Nagahori M, Ito H

Evaluation of a Mental Health Care App–Based Fatigue Management Program for Patients With Inflammatory Bowel Disease in Remission: Protocol for a Randomized Controlled Trial

JMIR Res Protoc 2026;15:e96593

DOI: 10.2196/96593

PMID: 42803779

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.